For the Inventor, By the Inventor

Enter assignee name

Nijmegen, Netherlands

Byondis B.v.

USPTO Granted Patents = 18

CIPO Patents = 9

EPO Patents = 10

Trademarks = 23

Forward Citations = 13

Loading Chart...

Loading Chart...

35 inventors (with patents filed for the assignee):

Rudy Gerardus Elisabeth Coumans (9 out of 16 patents)

Gerardus Joseph Andreas Ariaans (5 out of 8 patents)

Gijsbertus Franciscus Maria Verheijden (4 out of 6 patents)

4. Gerard Rouwendal (2 out of 2 patents)

5. Roland Jan Arends (2 out of 2 patents)

6. Timo Kars Van Den Berg (2 out of 9 patents)

7. Hanke Lottie Matlung (2 out of 2 patents)

8. Katarina Franke (2 out of 2 patents)

9. Miranda Maria Cornelia Van Der Lee (2 out of 2 patents)

10. Jan Schouten (2 out of 2 patents)

11. Marion Blomenrohr (2 out of 2 patents)

12. Patrick Gerhard Groothuis (2 out of 2 patents)

13. Patrick Henry Beusker (1 out of 14 patents)

14. Ronald Christiaan Elgersma (1 out of 6 patents)

15. Wiro Michael Petrus Bernardus Menge (1 out of 4 patents)

18 patents: Sort by Forward Citations

1. 12350345 - Dual conjugation process for preparing antibody-drug conjugates (2025-07-08),

2. 12180552 - Site-specific conjugation of linker drugs to antibodies and resulting ADCs (2024-12-31),

3. 12180295 - Humanized anti-SIRPα antibodies (2024-12-31),

4. 12178881 - Filterable duocarmycin-containing antibody-drug conjugate compositions and related methods (2024-12-31),

5. 11718681 - Anti-SIRP α antibodies (2023-08-08),

6. 11696958 - Dual conjugation process for preparing antibody-drug conjugates (2023-07-11),

7. 11633492 - Process for the synthesis of linker-drug vc-seco-DUBA (2023-04-25),

8. 11584801 - Anti-5T4 antibodies and antibody-drug conjugates (2023-02-21),

9. 11419944 - Non-linear self-immolative linkers and conjugates thereof (2022-08-23),

10. 11382982 - Duocarmycin ADCs showing improved in vivo antitumor activity (2022-07-12),

11. 11274159 - Anti-SIRPα antibodies (2022-03-15),

12. 11136633 - Site-specific conjugation of linker drugs to antibodies and resulting ADCS (2021-10-05),

13. 11104968 - Site-specific conjugation of linker drugs to antibodies and resulting ADCS (2021-08-31),

14. 11077204 - Compositions comprising antibody-duocarmycin drug conjugates (2021-08-03),

15. 11008400 - Anti-5T4 antibodies and antibody-drug conjugates (2021-05-18),

Byondis B.V. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative antibody-drug conjugates (ADCs) for the treatment of cancer. With a strong focus on precision medicine, Byondis aims to bring breakthrough therapies to patients by combining the targeting precision of antibodies with the potency of cytotoxic drugs. Byondis is committed to improving outcomes and quality of life for cancer patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

18 Patents

#5 in Nijmegen

#391 in Netherlands

#33,147 in the World

Nijmegen, Netherlands

Byondis B.v.

Forward Citations = 13

35 inventors:

Rudy Gerardus Elisabeth Coumans (9 out of 16 patents)

Gerardus Joseph Andreas Ariaans (5 out of 8 patents)

Gijsbertus Franciscus Maria Verheijden (4 out of 6 patents)

4. Gerard Rouwendal (2 out of 2 patents)

5. Roland Jan Arends (2 out of 2 patents)

Please report any incorrect information to support@idiyas.com

Loading…